H. Pylori Treatment
For treatment-naive patients, use 14-day bismuth quadruple therapy (BQT) as first-line empiric treatment, consisting of a PPI twice daily, bismuth subsalicylate 2 tablets four times daily, tetracycline 500 mg four times daily, and metronidazole 500 mg four times daily. 1
First-Line Treatment Options
The most recent 2022 guidelines establish that only two regimens can be reliably given empirically in most areas due to rising antibiotic resistance:
Primary Recommendation: Bismuth Quadruple Therapy (14 days)
- PPI (esomeprazole or rabeprazole 20-40 mg) twice daily, 30 minutes before meals
- Bismuth subsalicylate 2 tablets (262 mg each) four times daily, 30 minutes before meals
- Tetracycline 500 mg four times daily, 30 minutes after meals
- Metronidazole 500 mg four times daily, 30 minutes after meals
This regimen is preferred because it maintains efficacy even with metronidazole-resistant strains and avoids clarithromycin, which now has >30% resistance rates in most regions 1, 2.
Alternative: Rifabutin Triple Therapy (14 days)
- Rifabutin 150 mg twice daily
- Amoxicillin 1 g three times daily
- High-dose PPI (esomeprazole or rabeprazole 40 mg) twice daily
Use this when bismuth is unavailable or in patients without penicillin allergy. Rifabutin resistance remains rare, making this an effective empiric option 1.
Critical Treatment Principles
Duration matters: All guidelines converge on 14-day therapy for first-line treatment, as this consistently outperforms 10-day regimens 3. The goal is to succeed on the first attempt to avoid retreatment, reduce costs, and minimize development of further antibiotic resistance.
PPI selection is crucial: Avoid pantoprazole. Use esomeprazole 20-40 mg or rabeprazole 20-40 mg twice daily, as these have superior acid suppression compared to omeprazole or lansoprazole 1. Higher potency PPIs significantly improve outcomes, particularly with amoxicillin-containing regimens.
Obsolete Regimens to Avoid
Do not use these therapies empirically 1:
- Clarithromycin triple therapy (unless susceptibility confirmed)
- Sequential therapy
- Hybrid therapy
- Concomitant therapy (includes antibiotics that provide no benefit while increasing resistance)
These regimens are explicitly labeled as obsolete because they include antibiotics that offer no therapeutic benefit and only increase global antimicrobial resistance 1.
Treatment After First Failure
If bismuth quadruple therapy fails: Use levofloxacin triple therapy (PPI + amoxicillin 1 g twice daily + levofloxacin 500 mg daily) for 14 days, but only if local levofloxacin resistance is <15% 3.
If clarithromycin or levofloxacin was used previously: Switch to optimized bismuth quadruple therapy for 14 days. Never reuse clarithromycin or levofloxacin after failure, as resistance develops rapidly 3.
Key principle: Avoid repeating antibiotics that have already failed, particularly clarithromycin and levofloxacin. Metronidazole can be reused if combined with bismuth due to synergistic effects. Amoxicillin and tetracycline can be reused as resistance remains rare 3.
Special Populations
Penicillin allergy: Use bismuth quadruple therapy (which contains tetracycline, not penicillin). If the patient reports penicillin allergy after first treatment failure, refer for allergy testing, as most patients who believe they are allergic actually are not 3.
Common Pitfalls
- Do not substitute doxycycline for tetracycline in bismuth quadruple therapy—results are significantly inferior 1
- Do not use 10-day packaged Pylera® without extending to 14 days, as shorter duration reduces efficacy 1
- Do not use clarithromycin-based triple therapy empirically—resistance now exceeds 30% in most regions, making this ineffective 2, 4
- Avoid levofloxacin as first-line therapy due to rising resistance rates and FDA warnings about serious side effects 1
Cost Considerations
Generic tetracycline costs approximately $100 for 14 days with discount coupons (versus $660 retail). Bismuth subsalicylate is available over-the-counter. This makes bismuth quadruple therapy cost-effective when prescribed as individual components rather than combination products 1.